Results 31 to 40 of about 2,662,368 (270)

Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. [PDF]

, 2016
BackgroundCardiovascular disease, a progressive manifestation of α-L-iduronidase deficiency or mucopolysaccharidosis type I, continues in patients both untreated and treated with hematopoietic stem cell transplantation or intravenous enzyme replacement ...
Dickson, Patricia I, Ellinwood, N Matthew, Esko, Jeffrey D, Gordts, Philip L, Khalid, Omar, Schwartz, Philip H, Vera, Moin U, Wang, Raymond Y   +7 more
core   +15 more sources

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. [PDF]

Ann Oncol, 2020
Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, George S, Gronchi A, Haas RL, Hindi N, Hohenberger P, Joensuu H, Jones RL, Judson I, Kang YK, Kawai A, Lazar AJ, Le Cesne A, Maestro R, Maki RG, Martín J, Patel S, Penault-Llorca F, Premanand Raut C, Rutkowski P, Safwat A, Sbaraglia M, Schaefer IM, Shen L, Serrano C, Schöffski P, Stacchiotti S, Sundby Hall K, Tap WD, Thomas DM, Trent J, Valverde C, van der Graaf WTA, von Mehren M, Wagner A, Wardelmann E, Naito Y, Zalcberg J, Blay JY.   +47 more
europepmc   +2 more sources

Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors

Clinical Pathology, 2023
Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase ...
Mariana Petaccia de Macedo, Ellen Caroline Toledo Nascimento, Fernando Augusto Soares, Fernando Costa Santini, Felipe D’Almeida Costa, Isabela Werneck da Cunha, Rodrigo Ramella Munhoz, Pedro De Marchi, Thiago William Carnier Jorge, Kátia Ramos Moreira Leite   +9 more
doaj   +1 more source

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Frontiers in Oncology, 2022
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu, Yuxuan Wei, Huan Zhang, Jizong Jiang, Peng Zhang, Qian Chu   +5 more
doaj   +1 more source

gene amplification in patients with metastatic cancer [PDF]

Precision and Future Medicine, 2017
Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee, Nayoung K. D. Kim, Se-Hoon Lee, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Woong Yang Park, Hee Jin Bang, Kyoung-Mee Kim, Keunchil Park, Jeeyun Lee   +13 more
doaj   +1 more source

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Case Reports in Oncology, 2023
In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these ...
Lorenz Frehner, Simon Haefliger, Ferdinando Cerciello, Tobias Grob, Sabine Schmid   +4 more
doaj   +1 more source

Sedentary Conditions Promote Subregionally Specific Changes in Brain-Derived Neurotrophic Factor in the Rostral Ventrolateral Medulla

Frontiers in Physiology, 2021
A sedentary lifestyle is the top preventable cause of death and accounts for substantial socioeconomic costs to society. The rostral ventrolateral medulla regulates blood pressure under normal and pathophysiological states, and demonstrates inactivity ...
Bozena E. Fyk-Kolodziej, Patrick J. Mueller   +1 more
doaj   +1 more source

Resolving the binding-kinase discrepancy in bacterial chemotaxis: A nonequilibrium allosteric model and the role of energy dissipation [PDF]

Proc. Natl. Acad. Sci. U.S.A. 120, e2303115120 (2023), 2023
The Escherichia coli chemotaxis signaling pathway has served as a model system for studying the adaptive sensing of environmental signals by large protein complexes. The chemoreceptors control the kinase activity of CheA in response to the extracellular ligand concentration and adapt across a wide concentration range by undergoing methylation and ...
arxiv   +1 more source

Tropomyosin receptor kinase inhibitors in the management of sarcomas

Current Opinion in Oncology, 2020
Purpose of review Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas are rare and there is a significant challenge in identifying patients with sarcomas harbouring TRK fusions in
Wilding, CP, Loong, HH, Huang, PH, Jones, RL   +3 more
openaire   +5 more sources

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII [PDF]

Journal of Experimental & Clinical Cancer Research, 2018
Oncogenes derived from the neurotrophin receptor tropomyosin-related kinase TrkA act as drivers in sub-populations of a wide-range of human cancers. This, combined with a recent report that both adult and childhood cancers driven by novel oncogenic TrkA chimeric-fusions exhibit profound, long-lived therapeutic responses to the Trk inhibitor ...
Farina, Antonietta Rosella, Cappabianca, Lucia, Ruggeri, Pierdomenico, Gneo, Luciana, Pellegrini, Cristina, Fargnoli, Maria-Concetta, Mackay, Andrew Reay   +6 more
openaire   +4 more sources